Reading ABOS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ABOS free→Reading ABOS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ABOS free→NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral, and management's recent track record has been fairly steady. The company was unprofitable over the past year, so its earnings quality can't be assessed. Risk is elevated, and the sector backdrop is a headwind, which may impact future performance. If ABOS cuts guidance on the next call, that could be a meaningful negative, while positive momentum could come if sector bellwethers continue to beat earnings and guide higher. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $2.37. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Not enough peers to compare yet.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.93x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
5 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.46 → $-0.41 (+11.9% / 30d). 1 raised, 0 cut, 3 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$328.
How much price usually moves either way.
On a bad day, this stock has moved -$696.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,620.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If revenue growth in the healthcare sector picks up, it could benefit Acumen's performance. It shows a healthier market.
Confirms:Healthcare sector revenue growth is speeding up again toward 10% or more.
Disproves:Healthcare sector revenue growth keeps slowing down below current levels.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for ABOS yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
of this Report (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “ Securities Act ”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
No score history yet for this stock.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
ABOS Acumen Pharmaceuticals Inc | — | — | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 78 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Management aims to report topline results for the ALTITUDE-AD Phase 2 study investigating sabirnetug (ACU193) for early Alzheimer's disease by late 2026.
Newly stated in 2026-Q1. Management has set a target to report topline results for the ALTITUDE-AD Phase 2 study by late 2026. Financials show a net income loss of $20.7M in 2026-Q1, indicating ongoing investment in R&D. The trajectory is yet to be determined as this is a newly stated priority.
“Expect to report topline results for ALTITUDE-AD, a Phase 2 study, in late 2026.”
Management plans to submit an Investigational New Drug (IND) application for a lead clinical candidate by mid-2027.
Newly stated in 2026-Q1. Management targets submitting an IND for a lead clinical candidate by mid-2027. The financials show a net income loss of $20.7M in 2026-Q1, reflecting continued investment in development. The trajectory is yet to be determined as this is a newly stated priority.
“Submission of an IND with respect to a lead clinical candidate is targeted for mid-2027.”
The company continues to focus on capital allocation through private placements to support its operations.
Newly stated in 2026-Q1. The company has engaged in capital allocation through private placements, as evidenced by a Securities Purchase Agreement. Financials show a net income loss of $20.7M in 2026-Q1, indicating reliance on external funding. The trajectory is yet to be determined as this is a newly stated priority.
“The Company entered into a Securities Purchase Agreement for a private placement.”
Why it matters: The earnings report will show how the company is doing. It will also share future plans. Investors want to know the company's direction.
Confirms one read:An announcement of the next earnings report date within the next month.
Confirms the other:There is no news on when the next earnings report will be. This may mean delays or problems.
of this Report (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “ Securities Act ”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Entry into a Material Definitive Agreement. Securities Purchase Agreement On March 13, 2026, Acumen Pharmaceuticals, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain institutional accredited investors named therein (each, an “ Investor ” and collectively, the “ Investors ”), pursuant to which the Company agreed to sell to the Investors, in a private placement (the “ Private Placement ”), 10,833,331 shares (the “ Shares ”) of the Com…
Regulation FD Disclosure. On March 26, 2026, the Company posted an updated corporate presentation to its website at https://investors.acumenpharm.com/news-events/presentations, which the Company may use from time to time in communications or conferences. The corporate presentation was updated to reflect the Company’s cash, cash equivalents and marketable securities balance as of December 31, 2025 and to include the private placement completed by the Company on March 16, 2026. A copy of the co…
Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy any securities of the Company.